Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387431462> ?p ?o ?g. }
- W4387431462 endingPage "115863" @default.
- W4387431462 startingPage "115863" @default.
- W4387431462 abstract "In pursuance of our efforts to expand the scope of novel antileishmanial entities, a series of thirty-five quinoline-piperazine/pyrrolidine, and other heterocyclic amine derivatives were synthesized via a molecular hybridization approach and examined against intracellular amastigotes of luciferase-expressing Leishmania donovani. The preliminary in vitro screening suggests that twelve compounds in the series exhibited better inhibition against amastigote form with good IC50 values ranging from 2.09 to 8.89 μM and lesser cytotoxicity in contrast to the standard drug miltefosine (IC50 9.25 ± 0.17 μM). Based on the satisfactory selectivity index (SI), two compounds were tested for in vivo leishmanicidal efficacy against Leishmania donovani/golden hamster model. Compounds 33 and 46 have shown significant inhibition of 56.32%, and 49.29%, respectively, in vivo screening at a daily dose of 50 mg/kg for 5 days. The pharmacokinetic results confirmed that 33 and 46 have satisfactory IP exposure with adequate parameters. Collectively, Compound 33 was identified as the most significant potential lead that could be employed as a prototype for future optimizations." @default.
- W4387431462 created "2023-10-08" @default.
- W4387431462 creator A5007518427 @default.
- W4387431462 creator A5011303049 @default.
- W4387431462 creator A5015855020 @default.
- W4387431462 creator A5019025493 @default.
- W4387431462 creator A5022777308 @default.
- W4387431462 creator A5026078818 @default.
- W4387431462 creator A5034916132 @default.
- W4387431462 creator A5047203234 @default.
- W4387431462 creator A5053640497 @default.
- W4387431462 creator A5055237655 @default.
- W4387431462 creator A5085229814 @default.
- W4387431462 date "2023-10-01" @default.
- W4387431462 modified "2023-10-09" @default.
- W4387431462 title "Design, synthesis, and biological evaluation of quinoline-piperazine/pyrrolidine derivatives as possible antileishmanial agents" @default.
- W4387431462 cites W1125212322 @default.
- W4387431462 cites W1793361406 @default.
- W4387431462 cites W1893024652 @default.
- W4387431462 cites W1963542761 @default.
- W4387431462 cites W1965129579 @default.
- W4387431462 cites W1965579790 @default.
- W4387431462 cites W2010017271 @default.
- W4387431462 cites W2026554648 @default.
- W4387431462 cites W2038850624 @default.
- W4387431462 cites W2041896919 @default.
- W4387431462 cites W2067546903 @default.
- W4387431462 cites W2095697583 @default.
- W4387431462 cites W2108384965 @default.
- W4387431462 cites W2114918609 @default.
- W4387431462 cites W2121194231 @default.
- W4387431462 cites W2126812590 @default.
- W4387431462 cites W2129214516 @default.
- W4387431462 cites W2154316070 @default.
- W4387431462 cites W2198907191 @default.
- W4387431462 cites W2511087930 @default.
- W4387431462 cites W2605478093 @default.
- W4387431462 cites W2775643792 @default.
- W4387431462 cites W2804538994 @default.
- W4387431462 cites W2885688891 @default.
- W4387431462 cites W2896001545 @default.
- W4387431462 cites W2941757011 @default.
- W4387431462 cites W2945702797 @default.
- W4387431462 cites W2974769578 @default.
- W4387431462 cites W3043412581 @default.
- W4387431462 cites W3093536259 @default.
- W4387431462 cites W3157300054 @default.
- W4387431462 cites W3195268212 @default.
- W4387431462 cites W3199798576 @default.
- W4387431462 cites W4211073781 @default.
- W4387431462 cites W4362639392 @default.
- W4387431462 cites W4362684766 @default.
- W4387431462 cites W4377233181 @default.
- W4387431462 doi "https://doi.org/10.1016/j.ejmech.2023.115863" @default.
- W4387431462 hasPublicationYear "2023" @default.
- W4387431462 type Work @default.
- W4387431462 citedByCount "0" @default.
- W4387431462 crossrefType "journal-article" @default.
- W4387431462 hasAuthorship W4387431462A5007518427 @default.
- W4387431462 hasAuthorship W4387431462A5011303049 @default.
- W4387431462 hasAuthorship W4387431462A5015855020 @default.
- W4387431462 hasAuthorship W4387431462A5019025493 @default.
- W4387431462 hasAuthorship W4387431462A5022777308 @default.
- W4387431462 hasAuthorship W4387431462A5026078818 @default.
- W4387431462 hasAuthorship W4387431462A5034916132 @default.
- W4387431462 hasAuthorship W4387431462A5047203234 @default.
- W4387431462 hasAuthorship W4387431462A5053640497 @default.
- W4387431462 hasAuthorship W4387431462A5055237655 @default.
- W4387431462 hasAuthorship W4387431462A5085229814 @default.
- W4387431462 hasConcept C109316439 @default.
- W4387431462 hasConcept C136764020 @default.
- W4387431462 hasConcept C150903083 @default.
- W4387431462 hasConcept C178790620 @default.
- W4387431462 hasConcept C185592680 @default.
- W4387431462 hasConcept C202751555 @default.
- W4387431462 hasConcept C203014093 @default.
- W4387431462 hasConcept C207001950 @default.
- W4387431462 hasConcept C21951064 @default.
- W4387431462 hasConcept C2776201271 @default.
- W4387431462 hasConcept C2776309666 @default.
- W4387431462 hasConcept C2776555147 @default.
- W4387431462 hasConcept C2777752497 @default.
- W4387431462 hasConcept C2778689377 @default.
- W4387431462 hasConcept C2778851528 @default.
- W4387431462 hasConcept C2781092759 @default.
- W4387431462 hasConcept C2781333301 @default.
- W4387431462 hasConcept C2781417161 @default.
- W4387431462 hasConcept C41008148 @default.
- W4387431462 hasConcept C55493867 @default.
- W4387431462 hasConcept C71240020 @default.
- W4387431462 hasConcept C71928629 @default.
- W4387431462 hasConcept C86803240 @default.
- W4387431462 hasConcept C98274493 @default.
- W4387431462 hasConcept C98319499 @default.
- W4387431462 hasConceptScore W4387431462C109316439 @default.
- W4387431462 hasConceptScore W4387431462C136764020 @default.
- W4387431462 hasConceptScore W4387431462C150903083 @default.
- W4387431462 hasConceptScore W4387431462C178790620 @default.